Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: A retrospective case series

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1177-1187

  Pastewski, Andrew A ^a   Caruso, Patricia ^a   Parris, Addison R ^b   Dizon, Ramon ^c   Kopec, Robert ^d   Sharma, Shobha ^a   Mayer, Suri ^a   Ghitan, Monica ^a   Chapnick, Edward K ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b Rockingham Memorial Hospital   (United States)

^c St Vincent's Medical Center Jacksonville   (United States)

^d Morton Plant Hospital   (United States)

Author keywords

Bacteremia; Colistin; Polymyxin B; Urinary tract infection

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFEPIME; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN B; SULBACTAM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAM NEGATIVE INFECTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MALE; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMYXIN B; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 50249139019     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K346     Document Type: Article

References (30)

1. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. J Bacteriol 1947;54:24-5.
2. Brownlee G, Bushby SR, Short EI. The chemotherapy and pharmacology of polymyxins. Br J Pharmacol Chemother 1952;7:170-88.
3. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging mutiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-7. DOI 10.1345/aph.18426
4. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-5. DOI 10.1128/AAC.45.3.781-785.2001
5. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624-30. DOI 10.1128/AAC.49.9.3624-3630.2005
6. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-7. Epub 8 Feb 2007. DOI 10.1093/jac/dkl1512
7. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002;34:257-61. DOI 10.1002/ppul.10166
8. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:539-45.
9. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21. DOI 10.1586/14787210.5.5.811
10. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27. DOI 10.1186/cc3995
11. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
12. Wareham DW, Bean DC. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006;5:10. DOI 10.1186/1476-0711-5-10
13. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med 1964;270:1030-5.
14. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62. DOI 10.1128/AAC.47.8.2659-2662.2003
15. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46.
16. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. DOI 10.1086/514732
17. Sued O, Kelley GR, Nenna A, et al. Use of intravenous colistin for nosocomial infections. Presented at: 39th Annual Infectious Diseases Society of America Meeting, San Francisco, October 26, 2001.
18. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21. DOI 10.1111/j.1469-0691.2004.01043.x
19. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939-45. Epub 3 Oct 2006. DOI 10.1345/aph.1H353
20. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8. Epub 14 Apr 2003. DOI 10.1086/374337
21. Karabinis A, Paramythiotou E, Myona-Petropoulou D, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004;38:e7-9. Epub 4 Dec 2003. DOI 10.1086/380461
22. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-5. DOI 10.1128/AAC.00101-06
23. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40. DOI 10.1016/0196-6553(88)90053-3
24. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005; 40:1792-8. DOI 10.1086/430314
25. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004;25:842-6. DOI 10.1086/502306
26. NCCLS. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 5th ed. Approved standards document M7-A5. Wayne, PA: NCCLS, 2000.
27. Package insert. Polymyxin B for injection. Bedford, OH: Bedford Laboratories, 1999.
28. Hoeprich PD. The polymyxins. Med Clin North Am 1970;54:1257-65.
29. Pohlmann G. Respiratory arrest associated with intravenous administration of polymyxin B sulfate. JAMA 1966;196:181-3. DOI 10.1001/jama.196.2.181
30. Elwood CM, Lucas GD, Muehrcke RC. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 1966;118:326-34. DOI 10.1001/archinte.118.4.326